These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA; Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413 [TBL] [Abstract][Full Text] [Related]
6. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Schiavotto C; Castaman G; Rodeghiero F Haematologica; 1993; 78(6 Suppl 2):29-34. PubMed ID: 8039755 [TBL] [Abstract][Full Text] [Related]
7. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura. Dan K; Gomi S; Kuramoto A; Maekawa T; Nomura T Int J Hematol; 1992 Jun; 55(3):287-92. PubMed ID: 1498319 [TBL] [Abstract][Full Text] [Related]
8. The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study. Palandri F; Polverelli N; Catani L; Sollazzo D; Romano M; Levorato M; Vianelli N Am J Hematol; 2014 Nov; 89(11):1047-50. PubMed ID: 25103500 [TBL] [Abstract][Full Text] [Related]
9. The effect of platelet autoantibodies on the course of the disease and clinical response of patients with idiopathic thrombocytopenic purpura. Sikorska A; Konopka L; Maślanka K Int J Lab Hematol; 2008 Feb; 30(1):58-64. PubMed ID: 18190469 [TBL] [Abstract][Full Text] [Related]
10. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. Journeycake JM Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617 [TBL] [Abstract][Full Text] [Related]
11. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262 [TBL] [Abstract][Full Text] [Related]
12. Sequence of treatments for adults with primary immune thrombocytopenia. George JN Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032 [TBL] [Abstract][Full Text] [Related]
13. Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study. Pektaş G; Uncu İA; Dere Y; Öncü Ş; Kızılkaya MB; Sadi G; Pektaş MB Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064581 [No Abstract] [Full Text] [Related]
14. An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. Gwilliam NR; Lazar DA; Brandt ML; Mahoney DH; Wesson DE; Mazziotti MV; Nuchtern JG; Lee TC J Pediatr Surg; 2012 Aug; 47(8):1537-41. PubMed ID: 22901913 [TBL] [Abstract][Full Text] [Related]
15. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Palandri F; Polverelli N; Sollazzo D; Romano M; Catani L; Cavo M; Vianelli N Am J Hematol; 2016 Jun; 91(4):E267-72. PubMed ID: 26799593 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M; Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672 [TBL] [Abstract][Full Text] [Related]